Enasidenib
Enasidenib is an orally available, selective, potent, small molecule inhibitor of mutant isocitrate dehydrogenase 2 (IDH2). Neomorphic mutations in IDH2 are frequently found in both hematologic malignancies and solid tumors and lead to the production of the oncometabolite (R)-2-hydroxyglutarate. Inc...
Gespeichert in:
| Hauptverfasser: | , |
|---|---|
| Dokumenttyp: | Kapitel/Artikel |
| Sprache: | Englisch |
| Veröffentlicht: |
02 August 2018
|
| In: |
Small molecules in hematology
Year: 2018, Pages: 187-197 |
| DOI: | 10.1007/978-3-319-91439-8_9 |
| Online-Zugang: | Verlag, Volltext: https://doi.org/10.1007/978-3-319-91439-8_9
|
| Verfasserangaben: | Alwin Krämer, Tilmann Bochtler |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1680038494 | ||
| 003 | DE-627 | ||
| 005 | 20230426084703.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 191028s2018 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/978-3-319-91439-8_9 |2 doi | |
| 035 | |a (DE-627)1680038494 | ||
| 035 | |a (DE-599)KXP1680038494 | ||
| 035 | |a (OCoLC)1341249315 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Krämer, Alwin |e VerfasserIn |0 (DE-588)1067780025 |0 (DE-627)819183431 |0 (DE-576)426900820 |4 aut | |
| 245 | 1 | 0 | |a Enasidenib |c Alwin Krämer, Tilmann Bochtler |
| 264 | 1 | |c 02 August 2018 | |
| 300 | |a 11 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 28.10.2019 | ||
| 520 | |a Enasidenib is an orally available, selective, potent, small molecule inhibitor of mutant isocitrate dehydrogenase 2 (IDH2). Neomorphic mutations in IDH2 are frequently found in both hematologic malignancies and solid tumors and lead to the production of the oncometabolite (R)-2-hydroxyglutarate. Increased levels of (R)-2-hydroxyglutarate cause histone and DNA hypermethylation associated with blocked differentiation and tumorigenesis. In PDX mice transplanted with human IDH2-mutant acute myeloid leukemia cells, enasidenib treatment led to normalization of (R)-2-hydroxyglutarate serum levels, differentiation of leukemic blasts and increased survival. Early clinical data in patients with relapsed/refractory IDH2-mutant acute myeloid leukemia show that enasidenib is well tolerated and induces durable complete remissions as a single agent in about 20% of cases. One notable drug-related adverse effect is differentiation syndrome. On the basis of these results the compound has recently been approved for the treatment of relapsed/refractory IDH2-mutant acute myeloid leukemia in the USA. Although no data are available yet, clinical trials on the treatment of patients with several types of IDH2-mutant solid tumors including gliomas, chondrosarcomas and cholangiocarcinomas are currently being performed. | ||
| 650 | 4 | |a 2-hydroxyglutarate | |
| 650 | 4 | |a Acute myeloid leukemia | |
| 650 | 4 | |a AG-221 | |
| 650 | 4 | |a AML | |
| 650 | 4 | |a Glioblastoma | |
| 650 | 4 | |a Hypermethylation | |
| 650 | 4 | |a IDH | |
| 650 | 4 | |a Isocitrate dehydrogenase | |
| 650 | 4 | |a Ketoglutarate | |
| 700 | 1 | |a Bochtler, Tilmann |d 1975- |e VerfasserIn |0 (DE-588)128398957 |0 (DE-627)372639925 |0 (DE-576)187323909 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Small molecules in hematology |b Third edition |d Cham, Switzerland : Springer, 2018 |g (2018), Seite 187-197 |h 1 Online-Ressource (VIII, 294 Seiten) |w (DE-627)1030110891 |w (DE-576)510624774 |z 9783319914398 |7 nnam |a Enasidenib |
| 773 | 1 | 8 | |g year:2018 |g pages:187-197 |g extent:11 |a Enasidenib |
| 856 | 4 | 0 | |u https://doi.org/10.1007/978-3-319-91439-8_9 |x Verlag |x Resolving-System |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20191028 | ||
| 993 | |a BookComponentPart | ||
| 994 | |a 2018 | ||
| 998 | |g 128398957 |a Bochtler, Tilmann |m 128398957:Bochtler, Tilmann |d 910000 |d 910100 |e 910000PB128398957 |e 910100PB128398957 |k 0/910000/ |k 1/910000/910100/ |p 2 |y j | ||
| 998 | |g 1067780025 |a Krämer, Alwin |m 1067780025:Krämer, Alwin |d 910000 |d 910100 |e 910000PK1067780025 |e 910100PK1067780025 |k 0/910000/ |k 1/910000/910100/ |p 1 |x j | ||
| 999 | |a KXP-PPN1680038494 |e 3529196339 | ||
| BIB | |a Y | ||
| JSO | |a {"origin":[{"dateIssuedKey":"2018","dateIssuedDisp":"02 August 2018"}],"recId":"1680038494","type":{"media":"Online-Ressource","bibl":"chapter"},"relHost":[{"person":[{"display":"Martens, Uwe Marc","role":"edt","given":"Uwe Marc","family":"Martens"}],"relMultPart":[{"pubHistory":["Nachgewiesen 165.2006 -"],"language":["eng"],"part":{"number":["volume 212"],"number_sort":["212"]},"title":[{"title":"Recent results in cancer research","title_sort":"Recent results in cancer research"}],"note":["Gesehen am 25.10.07"],"physDesc":[{"extent":"Online-Ressource"}],"id":{"issn":["2197-6767"],"zdb":["2393522-4"],"eki":["548128227"]},"disp":"Recent results in cancer research","type":{"media":"Online-Ressource","bibl":"serial"},"recId":"548128227","origin":[{"dateIssuedDisp":"2006-","publisher":"Springer","dateIssuedKey":"2006","publisherPlace":"Berlin ; Heidelberg"}],"dispAlt":"Recent results in cancer research"}],"name":{"displayForm":["Uwe M. Martens, editor"]},"disp":"EnasidenibSmall molecules in hematology","id":{"eki":["1030110891"],"isbn":["9783319914398"],"doi":["10.1007/978-3-319-91439-8"]},"physDesc":[{"noteIll":"Illustrationen, Diagramme","extent":"1 Online-Ressource (VIII, 294 Seiten)"}],"recId":"1030110891","origin":[{"dateIssuedDisp":"[2018]","publisher":"Springer","dateIssuedKey":"2018","edition":"Third edition","editionNo":3,"publisherPlace":"Cham, Switzerland"}],"type":{"media":"Online-Ressource","bibl":"edited-book"},"title":[{"title_sort":"Small molecules in hematology","title":"Small molecules in hematology"}],"part":{"year":"2018","text":"(2018), Seite 187-197","pages":"187-197","extent":"11"},"language":["eng"]}],"note":["Gesehen am 28.10.2019"],"id":{"eki":["1680038494"],"doi":["10.1007/978-3-319-91439-8_9"]},"physDesc":[{"extent":"11 S."}],"name":{"displayForm":["Alwin Krämer, Tilmann Bochtler"]},"person":[{"given":"Alwin","role":"aut","display":"Krämer, Alwin","family":"Krämer"},{"family":"Bochtler","role":"aut","given":"Tilmann","display":"Bochtler, Tilmann"}],"language":["eng"],"title":[{"title":"Enasidenib","title_sort":"Enasidenib"}]} | ||
| SRT | |a KRAEMERALWENASIDENIB0220 | ||